October 23–27, 2026 | Madrid, Spain
Date: October 23–27, 2026
Exhibit location:
IFEMA Madrid
Avda. Del Partenón, 5
28042 Madrid (Spain)
Booth:
Booth 8026
Friday, October 23: 10:00 am – 6:30 pm
Saturday, October 24: 10:00 – 6:30 pm
Sunday, October 25: 10:00 – 6:30 pm
Monday, October 26: 10:00 – 6:30 pm
| Date/Time | Title | Abstract # ▲ ▼ | Type ▲ ▼ | Category | Author ▲ ▼ | Location |
|---|---|---|---|---|---|---|
|
Saturday, October 24, 2026 12:00 - 12:45 |
Phase 1b/2 trial of BGB-A445 (OX40 Agonist) with or without tislelizumab in urothelial carcinoma, renal cell carcinoma, and melanoma |
5333 | Poster | BGB-A445, Tislelizumab | Bin Lian, MD | Hall 5 |
|
Sunday, October 25, 2026 12:00 - 12:45 |
Impact of progressive disease patterns on post-progression overall survival in esophageal squamous cell carcinoma: A post hoc analysis of RATIONALE-302 |
4190 | Poster | Tislelizumab | Jhe-Cyuan Guo, MD, PhD | Hall 5 |
|
Sunday, October 25, 2026 12:00 - 12:45 |
RATIONALE-305: Post-treatment immuno-oncology adjustment analysis to assess tislelizumab treatment effect vs placebo |
4229 | Poster | Tislelizumab | Markus Moehler, MD, PhD | Hall 5 |
|
Monday, October 26, 2026 12:00 - 12:45 |
RATIONALE-312: Exploratory analysis of tislelizumab plus platinum-etoposide on brain disease progression in first-line extensive-stage small cell lung cancer |
2900 | Poster | Tislelizumab | Francesco Passiglia, MD, PhD | Hall 5 |
|
Monday, October 26, 2026 12:00 - 12:45 |
RATIONALE-315: Clinical outcomes by adjuvant treatment cycles in perioperative tislelizumab plus chemotherapy in resectable NSCLC |
3698 | Poster | Tislelizumab | Ernest Nadal, MD, PhD | Hall 5 |
|
Saturday, October 24, 2026 12:00 - 12:45 |
KANDELA-302: A phase 3, global, open-label, randomized study of the selective CDK4 inhibitor BGB-43395 + letrozole vs CDK4/6 inhibitors + letrozole for first-line treatment of advanced or metastatic HR+/HER2− breast cancer |
7137 | Poster | BGB-43395 | Sara M. Tolaney, MD, MPH | Hall 5 |
|
Monday, October 26, 2026 12:00 - 12:45 |
First-in-human study of BG-C477, a novel CEA-targeting ADC, in advanced solid tumors: initial results in NSCLC |
6042 | Poster | BG-C477 | Matthew Lee, MD, MPH | Hall 5 |
|
Saturday, October 24, 2026 10:15 – 11:45 |
Phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy: First disclosure of dose optimization and dose escalation update in advanced hepatocellular carcinoma |
6774 | Oral | BGB-B2033 | Hong Jae Chon, MD, PhD | Alicante Auditorium - Hall 6 |
|
Friday, October 23, 2026 15:15 - 16:00 |
First-in-human trial of BGB-58067, an MTA-cooperative PRMT5 Inhibitor, in MTAP-deficient advanced tumors |
5392 | Poster | BGB-58067 | Jordi Rodon Ahnert, MD, PhD | Hall 5 |
|
Sunday, October 25, 2026 12:00 - 12:45 |
Exposure-adjusted analyses of safety patterns in HERIZON-GEA-01: Zanidatamab with and without tislelizumab and chemotherapy in 1L HER2+ metastatic gastroesophageal adenocarcinoma |
4484 | Poster | Tislelizumab, Zanidatamab | Sun Young Rha, MD, PhD | Hall 5 |
|
Friday, October 23, 2026 16:15 - 17:45 |
Zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive advanced/metastatic gastroesophageal adenocarcinoma: Second interim analysis from HERIZON-GEA-01 |
1749 | Rapid Oral | Tislelizumab, Zanidatamab | Kohei Shitara, MD | Almeria Auditorium - Hall 9 |
